Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second leading cause of pediatric cancer-related death in developed countries. While the cure rate for newly diagnosed ALL is excellent, the genetic heterogeneity and chemoresistance of leukemia cells at relapse makes individualized curative treatment plans difficult. We hypothesize that genetic events would coalesce into a finite number of protein signatures that could guide the design of individualized therapy. Custom reverse-phase protein arrays were produced from pediatric ALL (n = 73) and normal CD34(+) (n = 10) samples with 194 validated antibodies. Proteins were allocated into 31 protein functional groups (PFG) to analyze them in the context...
Parallel to fingerprinting of leukemia subclasses by gene expression profiling we propose to fingerp...
Our understanding of the genetic etiology of pediatric acute lymphoblastic leukemia (ALL) has advanc...
Acute lymphoblastic leukemia (ALL) is the most frequent malignant disease in the pediatric populatio...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Heterogeneity in the genetic landscape of pediatric acute myeloid leukemia (AML) makes personalized ...
Despite impressive improvements in overall survival, (pediatric) acute leukemia remains a life-threa...
AbstractTreatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailori...
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in childhood population. ALL is a h...
Almost a quarter of pediatric patients with acute lymphoblastic leukemia (ALL) suffer from relapses....
The mechanisms driving clonal heterogeneity and evolution in relapsed pediatric acute lymphoblastic ...
Precursor B-acute lymphoblastic leukemia (pB-ALL) is a heterogeneous disease and multiparameter flow...
Acute lymphoblastic leukemia (ALL) is a prevalent disorder with a peak incidence in 2-to-5-year-old ...
Precursor B-acute lymphoblastic leukemia (pB-ALL) is a heterogeneous disease and multiparameter flow...
Parallel to fingerprinting of leukemia subclasses by gene expression profiling we propose to fingerp...
Our understanding of the genetic etiology of pediatric acute lymphoblastic leukemia (ALL) has advanc...
Acute lymphoblastic leukemia (ALL) is the most frequent malignant disease in the pediatric populatio...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Pediatric acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, and the second...
Heterogeneity in the genetic landscape of pediatric acute myeloid leukemia (AML) makes personalized ...
Despite impressive improvements in overall survival, (pediatric) acute leukemia remains a life-threa...
AbstractTreatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailori...
Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in childhood population. ALL is a h...
Almost a quarter of pediatric patients with acute lymphoblastic leukemia (ALL) suffer from relapses....
The mechanisms driving clonal heterogeneity and evolution in relapsed pediatric acute lymphoblastic ...
Precursor B-acute lymphoblastic leukemia (pB-ALL) is a heterogeneous disease and multiparameter flow...
Acute lymphoblastic leukemia (ALL) is a prevalent disorder with a peak incidence in 2-to-5-year-old ...
Precursor B-acute lymphoblastic leukemia (pB-ALL) is a heterogeneous disease and multiparameter flow...
Parallel to fingerprinting of leukemia subclasses by gene expression profiling we propose to fingerp...
Our understanding of the genetic etiology of pediatric acute lymphoblastic leukemia (ALL) has advanc...
Acute lymphoblastic leukemia (ALL) is the most frequent malignant disease in the pediatric populatio...